PetVivo (PETV) Q4 2025 earnings summary

Executive summary

• Achieved record revenues of $1.1 million, up 17% year-over-year, driven by expanded distributor networks, entry into new international markets like Mexico, and growth in the companion animal segment.

• Broadened product platform through new partnerships and innovative technologies, including diagnostics, medical treatments, AI-driven pet behavior analysis, and regenerative therapies.

• Strengthened leadership and commercial teams with key executive appointments to enhance operational and commercialization capabilities.

• SpryngⓇ administered by over 1,000 veterinary clinics nationwide, with significant adoption in both equine and companion animal segments.

Financial highlights

• Revenues increased 17% to $1.1 million; distributor network sales rose 31% to $958,000, representing 85-86% of total revenues.

• Gross profit reached $995,000, representing 87.8% of revenues, up 15% year-over-year.

• Operating expenses decreased 21% to $9.1 million, and operating loss decreased 24% to $8.1 million.

• Net loss improved by 27% to $8 million ($0.39 per share), with net cash used in operations down 40% year-over-year.

• Cash and cash equivalents at year-end were $227,689, up from $87,403, and rose to $3.3 million post-year-end via equity financing.

Outlook and guidance

• Raised $4.7 million post-year-end via Series B convertible preferred stock to support fiscal 2026 growth strategies.

• Expects another year of record growth and improved bottom line for fiscal 2026, leveraging expanded sales force, distributor network, and new products.

• U.S. animal health market projected to double to $11.3 billion by 2030, providing significant growth tailwinds.